Does Gemfibrozil Interact with Glibenclamide?
The gemfibrozil label names glyburide, also called glibenclamide, among OATP1B1 substrates whose exposure may increase when this transporter is inhibited.
Label evidence and limitations
Named-drug label evidence. The label discusses possible clinician-directed dose reduction. CDI’s severity category is not an FDA-assigned rating.
Product scope: Oral gemfibrozil tablets; glyburide/glibenclamide identity.
Read the DailyMed label: GEMFIBROZIL TABLETS USP, 600 mg - gemfibrozil tablets
Section: Drug Interactions — OATP1B1 substrates. Compared version 102, label date 2023-10-24. The linked label may be updated after this comparison.
This comparison uses the label identifier saved with the CDI record. The compared version may be newer than the original extraction.
NIH PubChem identity reference: glyburide / glibenclamide
AI-assisted source comparison dated 2026-10-16. This is a comparison of label text, not independent clinical review or an individual safety assessment. CDI's stored severity category is not an FDA-assigned rating. Confirm your exact medicines and formulations with your pharmacist or prescriber before changing treatment.
- Stored CDI classification
- Moderate
- Gemfibrozil Class
- Peroxisome Proliferator Receptor alpha Agonist
- Glibenclamide Class
- Sulfonylurea
- Management
- Confirm exact products with your pharmacist
- Data Source
- Product label via NLM DailyMed
What To Tell Your Doctor or Pharmacist
If you are taking Gemfibrozil and your doctor is considering prescribing Glibenclamide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Never stop or change either medication without first consulting your healthcare provider